Teacher Retirement System of Texas lowered its position in OPKO Health (NASDAQ:OPK) by 34.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,287 shares of the biotechnology company’s stock after selling 38,370 shares during the quarter. Teacher Retirement System of Texas’ holdings in OPKO Health were worth $235,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. X Square Capital LLC acquired a new position in OPKO Health in the 4th quarter worth $2,363,000. Delek Group Ltd. acquired a new position in OPKO Health in the 4th quarter worth $382,000. Boulegeris Investments Inc. increased its position in shares of OPKO Health by 19.3% in the 4th quarter. Boulegeris Investments Inc. now owns 228,780 shares of the biotechnology company’s stock worth $1,121,000 after purchasing an additional 36,950 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in shares of OPKO Health by 18.0% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 340,326 shares of the biotechnology company’s stock worth $1,668,000 after purchasing an additional 51,890 shares during the last quarter. Finally, Raymond James & Associates increased its position in shares of OPKO Health by 36.4% in the 4th quarter. Raymond James & Associates now owns 332,514 shares of the biotechnology company’s stock worth $1,629,000 after purchasing an additional 88,725 shares during the last quarter. Hedge funds and other institutional investors own 23.81% of the company’s stock.
In other OPKO Health news, Director Robert Scott Fishel acquired 15,000 shares of the stock in a transaction that occurred on Monday, April 16th. The stock was acquired at an average price of $3.01 per share, with a total value of $45,150.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Phillip Md Et Al Frost acquired 10,000 shares of the stock in a transaction that occurred on Thursday, April 5th. The shares were acquired at an average cost of $3.25 per share, with a total value of $32,500.00. Following the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $9,974,090.75. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 1,122,701 shares of company stock valued at $3,749,965. Insiders own 42.74% of the company’s stock.
Shares of NASDAQ:OPK opened at $4.57 on Monday. The company has a quick ratio of 0.94, a current ratio of 1.10 and a debt-to-equity ratio of 0.03. OPKO Health has a fifty-two week low of $2.66 and a fifty-two week high of $7.25. The stock has a market cap of $2.56 billion, a P/E ratio of -15.76 and a beta of 1.67.
OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. OPKO Health had a negative net margin of 31.27% and a negative return on equity of 8.76%. The business had revenue of $254.90 million during the quarter, compared to the consensus estimate of $236.90 million. During the same quarter in the prior year, the firm earned ($0.06) EPS. The company’s revenue for the quarter was down 4.3% compared to the same quarter last year. equities analysts expect that OPKO Health will post -0.27 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on the stock. Barrington Research reissued a “buy” rating and issued a $7.00 target price on shares of OPKO Health in a research report on Wednesday, May 9th. ValuEngine raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Zacks Investment Research downgraded shares of OPKO Health from a “buy” rating to a “hold” rating in a research report on Friday, May 25th. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 target price on shares of OPKO Health in a research report on Tuesday, May 8th. Finally, BidaskClub raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $10.21.
OPKO Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OPKO Health (NASDAQ:OPK).
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.